SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Olsson Erik J.) srt2:(2005-2009)"

Sökning: WFRF:(Olsson Erik J.) > (2005-2009)

  • Resultat 1-48 av 48
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Olsson, Erik J, et al. (författare)
  • Introduction: The Pragmatism of Isaac Levi
  • 2006
  • Ingår i: Knowledge and Inquiry: Essays on the Pragmatism of Isaac Levi. - 9780521845564 ; , s. 1-17
  • Bokkapitel (refereegranskat)
  •  
2.
  • Olsson, Erik J, et al. (författare)
  • Levi and the Lottery
  • 2006
  • Ingår i: Knowledge and Inquiry: Essays on the Pragmatism of Isaac Levi. - 9780521845564 ; , s. 167-178
  • Bokkapitel (refereegranskat)
  •  
3.
  • Olsson, Erik J, et al. (författare)
  • Potential Answers - to What Question?
  • 2006
  • Ingår i: Knowledge and Inquiry: Essays on the Pragmatism of Isaac Levi. - 9780521845564 ; , s. 157-166
  • Bokkapitel (refereegranskat)
  •  
4.
  • Brown, Darron R., et al. (författare)
  • The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
  • 2009
  • Ingår i: Journal Of Infectious Diseases. - : Oxford University Press (OUP). - 0022-1899 .- 1537-6613. ; 199:7, s. 926-935
  • Konferensbidrag (refereegranskat)abstract
    • Background. Human papillomavirus (HPV)-6/11/16/18 vaccine reduces the risk of HPV-6/11/16/18-related cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS). Here, its impact on CIN1-3/AIS associated with nonvaccine oncogenic HPV types was evaluated. Methods. We enrolled 17,622 women aged 16-26 years. All underwent cervicovaginal sampling and Pap testing at regular intervals for up to 4 years. HPV genotying was performed for biopsy samples, and histological diagnoses were determined by a pathology panel. Analyses were conducted among subjects who were negative for 14 HPV types on day 1. Prespecified analyses included infection of >= 6 months' duration and CIN1-3/AIS due to the 2 and 5 most common HPV types in cervical cancer after HPV types 16 and 18, as well as all tested nonvaccine types. Results. Vaccination reduced the incidence of HPV-31/45 infection by 40.3% (95% confidence interval [CI], 13.9% to 59.0%) and of CIN1-3/AIS by 43.6% (95% CI, 12.9% to 64.1%), respectively. The reduction in HPV-31/33/45/52/58 infection and CIN1-3/AIS was 25.0% (95% CI, 5.0% to 40.9%) and 29.2% (95% CI, 8.3% to 45.5%), respectively. Efficacy for CIN2-3/AIS associated with the 10 nonvaccine HPV types was 32.5% (95% CI, 6.0% to 51.9%). Reductions were most notable for HPV-31. Conclusions. HPV-6/11/16/18 vaccine reduced the risk of CIN2-3/AIS associated with nonvaccine types responsible for similar to 20% of cervical cancers. The clinical benefit of cross-protection is not expected to be fully additive to the efficacy already observed against HPV-6/11/16/18-related disease, because women may have >1 CIN lesion, each associated with a different HPV type.
  •  
5.
  • von Haartman, Martin, et al. (författare)
  • Low-frequency noise and Coulomb scattering in Si0.8Ge0.2 surface channel pMOSFETs with ALD Al2O3 gate dielectrics
  • 2005
  • Ingår i: Solid-State Electronics. - : Elsevier BV. - 0038-1101 .- 1879-2405. ; 49:6, s. 907-914
  • Tidskriftsartikel (refereegranskat)abstract
    • Carrier mobility and low-frequency noise were investigated in Si0.8Ge0.2 surface channel pMOSFETs with ALD Al2O3 gate dielectrics. The devices were annealed in H2O Vapor, which reduced the negative charge in the gate dielectrics. The carrier mobility was characterized versus change in oxide charge, which allowed an estimation of the Coulomb scattering from the charge in the Al2O3. The low-frequency noise was measured between subthreshold and strong inversion conditions in the H2O annealed and the un-annealed devices. The combined number fluctuation and correlated mobility fluctuation noise model could successfully explain the observed 1/f noise. The mobility fluctuations were negatively correlated to the number fluctuations in the un-annealed devices, which contained a negative oxide charge. In the H2O annealed devices, on the other hand, a positive correlation could be observed. The maximum magnitude of the scattering parameter a was found to be around 1 X 10(4) Vs/C. The H2O annealing was used in this work as a non-destructive tool to modify the charge in the Al2O3, but it can also be a viable method to improve device performance by introducing/passivating charge.
  •  
6.
  • Wheeler, Cosette M., et al. (författare)
  • The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years
  • 2009
  • Ingår i: Journal Of Infectious Diseases. - : Oxford University Press (OUP). - 0022-1899 .- 1537-6613. ; 199:7, s. 936-944
  • Konferensbidrag (refereegranskat)abstract
    • Background. We evaluated the impact of a quadrivalent human papillomavirus (HPV) vaccine on infection and cervical disease related to 10 nonvaccine HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) associated with >20% of cervical cancers. The population evaluated included HPV-naive women and women with preexisting HPV infection and/or HPV-related disease at enrollment. Methods. Phase 3 efficacy studies enrolled 17,622 women aged 16-26 years. Subjects underwent cervicovaginal sampling and Pap testing on day 1 and then at 6-12-month intervals for up to 4 years. HPV typing was performed on samples from enrollment and follow-up visits, including samples obtained for diagnosis or treatment of HPV-related disease. All subjects who received >= 1 dose and returned for follow-up were included. Results. Vaccination reduced the rate of HPV-31/33/45/52/58 infection by 17.7% (95% confidence interval [CI], 5.1% to 28.7%) and of cervical intraepithelial neoplasia (CIN) 1-3 or adenocarcinoma in situ (AIS) by 18.8% (95% CI, 7.4% to 28.9%). Vaccination also reduced the rate of HPV-31/58/59-related CIN1-3/AIS by 26.0% (95% CI, 6.7% to 41.4%), 28.1% (95% CI, 5.3% to 45.6%), and 37.6% (95% CI, 6.0% to 59.1%), respectively. Although a modest reduction in HPV-31/33/45/52/58-related CIN2 or worse was observed, the estimated reduction was not statistically significant. Conclusions. These cross-protection results complement the vaccine's prophylactic efficacy against disease associated with HPV-6, -11, -16, and - 18. Long-term monitoring of vaccinated populations are needed to fully ascertain the population-based impact and public health significance of these findings.
  •  
7.
  •  
8.
  • Eriksson, Anders, et al. (författare)
  • RPC-LAP : The Rosetta Langmuir probe instrument
  • 2007
  • Ingår i: Space Science Reviews. - : Springer Science and Business Media LLC. - 0038-6308 .- 1572-9672. ; 128:04-jan, s. 729-744
  • Forskningsöversikt (refereegranskat)abstract
    • The Rosetta dual Langmuir probe instrument, LAP, utilizes the multiple powers of a pair of spherical Langmuir probes for measurements of basic plasma parameters with the aim of providing detailed knowledge of the outgassing, ionization, and subsequent plasma processes around the Rosetta target comet. The fundamental plasma properties to be studied are the plasma density, the electron temperature, and the plasma flow velocity. However, study of electric fields up to 8 kHz, plasma density fluctuations, spacecraft potential, integrated UV flux, and dust impacts is also possible. LAP is fully integrated in the Rosetta Plasma Consortium (RPC), the instruments of which together provide a comprehensive characterization of the cometary plasma.
  •  
9.
  •  
10.
  • Hansson, Bengt, et al. (författare)
  • Infallibility and incorrigibility
  • 2006
  • Ingår i: Knowledge and Inquiry. - 0521845564
  • Bokkapitel (övrigt vetenskapligt/konstnärligt)
  •  
11.
  • Kjaer, Susanne K., et al. (författare)
  • A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
  • 2009
  • Ingår i: Cancer Prevention Research. - 1940-6207. ; 2:10, s. 868-878
  • Tidskriftsartikel (refereegranskat)abstract
    • Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/16/18-related cervical, vaginal, and vulvar disease through 3 years. We provide an update on the efficacy of the quadrivalent HPV vaccine against high-grade cervical, vaginal, and vulvar lesions based on end-of-study data from three clinical trials. Additionally, we stratify vaccine efficacy by several baseline characteristics, including age, smoking status, and Papanicolaou (Pap) test results. A total of 18,174 females ages 16 to 26 years were randomized and allocated into one of three clinical trials (protocols 007, 013, and 015). Vaccine or placebo was given at baseline, month 2, and month 6. Pap testing was conducted at regular intervals. Cervical and anogenital swabs were collected for HPV DNA testing. Examination for the presence of vulvar and vaginal lesions was also done. Endpoints included high-grade cervical, vulvar, or vaginal lesions (CIN 2/3, VIN 2/3, or VaIN 2/3). Mean follow-up time was 42 months post dose 1. Vaccine efficacy against HPV 6/11/16/18-related high-grade cervical lesions in the per-protocol and intention-to-treat populations was 98.2% [95% confidence interval (95% CI), 93.3-99.8] and 51.5% (95% CI, 40.6-60.6), respectively. Vaccine efficacy against HPV 6/11/16/18-related high-grade vulvar and vaginal lesions in the per-protocol and intention-to-treat populations was 100.0% (95% CI, 82.6-100.0) and 79.0% (95% CI, 56.4-91.0), respectively. Efficacy in the intention-to-treat population tended to be lower in older women, women with more partners, and women with abnormal Pap test results. The efficacy of quadrivalent HPV vaccine against high-grade cervical and external anogenital neoplasia remains high through 42 months post vaccination.
  •  
12.
  •  
13.
  •  
14.
  • Musulin, Estanislao, et al. (författare)
  • Closing the Information Loop in Recipe-Based Batch Production
  • 2005
  • Ingår i: European Symposium on Computer-Aided Process Engineering-15 : 38th European Symposium of the Working Party on Computer Aided Process Engineering : ESCAPE-15 (Computer-aided chemical engineering). - 1570-7946. - 0444519874 ; 20, s. 1381-1386
  • Konferensbidrag (refereegranskat)abstract
    • In addition to the basic regulatory functions, a batch control system must support production planning and scheduling, recipe management, resource allocation, batch report generation, unit supervision and exception handling. A closed-loop framework is presented in this work that integrates decision support tools required at the different levels of a decision-making hierarchical batch control system. Specifically, the proposed framework consists of a reactive batch scheduler (MOPP) and a fault diagnosis system (ExSit-M) developed by the Universitat Politècnica de Catalunya, and a S88-recipe-based coordinator (JGrafchart) developed by the Lund University. These tools need to exchange information to obtain optimal utilization of the production plant. The complete integrated system is built using a general recipe description and other guidelines from ISA S88 standard.
  •  
15.
  •  
16.
  •  
17.
  •  
18.
  • Olsson, Erik J (författare)
  • Guest editor's introduction
  • 2007
  • Ingår i: Synthese. - : Springer Science and Business Media LLC. - 0039-7857 .- 1573-0964. ; 157:3, s. 267-274
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
19.
  •  
20.
  • Olsson, Erik J (författare)
  • Har kunskapen ett (mer)värde?
  • 2009
  • Ingår i: Filosofisk tidskrift. - 0348-7482. ; 3
  • Tidskriftsartikel (refereegranskat)
  •  
21.
  •  
22.
  •  
23.
  •  
24.
  • Olsson, Erik J (författare)
  • Kunskap och koherens
  • 2007
  • Ingår i: Filosofisk tidskrift. - 0348-7482.
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
25.
  •  
26.
  • Olsson, Erik J, et al. (författare)
  • On the Role of the Research Agenda in Epistemic Change
  • 2006
  • Ingår i: Erkenntnis. - : Springer Science and Business Media LLC. - 1572-8420 .- 0165-0106. ; 65:2, s. 165-183
  • Tidskriftsartikel (refereegranskat)abstract
    • The standard way of representing an epistemic state in formal philosophy is in terms of a set of sentences, corresponding to the agent's beliefs, and an ordering of those sentences, reflecting how well entrenched they are in the agent's epistemic state. We argue that this wide-spread representational view-a view that we identify as a "Quinean dogma" - is incapable of making certain crucial distinctions. We propose, as a remedy, that any adequate representation of epistemic states must also include the agent's research agenda, i.e., the list of question that are open or closed at any given point in time. If the argument of the paper is sound, a person's questions and practical interests, on the one hand, and her beliefs and theoretical values, on the other, are more tightly interwoven than has previously been assumed to be the case in formal epistemology.
  •  
27.
  •  
28.
  •  
29.
  • Olsson, Erik J, et al. (författare)
  • Reliability conducive measures of coherence
  • 2007
  • Ingår i: Synthese. - : Springer Science and Business Media LLC. - 0039-7857 .- 1573-0964. ; 157:3, s. 297-308
  • Tidskriftsartikel (refereegranskat)abstract
    • A measure of coherence is said to be truth conducive if and only if a higher degree of coherence (as measured) results in a higher likelihood of truth. Recent impossibility results strongly indicate that there are no (non-trivial) probabilistic coherence measures that are truth conducive. Indeed, this holds even if truth conduciveness is understood in a weak ceteris paribus sense (Bovens & Hartmann, 2003, Bayesian epistemology. New York, Oxford: Oxford University Press; Olsson, 2005, Against coherence: Truth probability and justification. Oxford: Oxford University Press). This raises the problem of how coherence could nonetheless be an epistemically important property. Our proposal is that coherence may be linked in a certain way to reliability. We define a measure of coherence to be reliability conducive if and only if a higher degree of coherence (as measured) results in a higher probability that the information sources are reliable. Restricting ourselves to the most basic case, we investigate which coherence measures in the literature are reliability conducive. It turns out that, while a number of measures fail to be reliability conducive, except possibly in a trivial and uninteresting sense, Shogenji's measure and several measures generated by Douven and Meijs's recipe are notable exceptions to this rule.
  •  
30.
  •  
31.
  •  
32.
  • Olsson, Erik J (författare)
  • Review of Epistemic Luck
  • 2007
  • Ingår i: Theoria: a Swedish Journal of Philosophy. - 0040-5825. ; 73:2, s. 172-178
  • Recension (övrigt vetenskapligt/konstnärligt)
  •  
33.
  •  
34.
  •  
35.
  • Olsson, Erik J (författare)
  • The Impossibility of Coherence
  • 2005
  • Ingår i: Erkenntnis. - : Springer Science and Business Media LLC. - 1572-8420 .- 0165-0106. ; 63:3, s. 387-412
  • Tidskriftsartikel (refereegranskat)
  •  
36.
  • Olsson, Erik J, et al. (författare)
  • The Impossibility of Coherence
  • 2007
  • Ingår i: Coherence, Truth and Testimony. - 9781402044267 ; , s. 95-120
  • Bokkapitel (övrigt vetenskapligt/konstnärligt)
  •  
37.
  • Olsson, Erik J, et al. (författare)
  • The Place of Coherence in Epistemology
  • 2007
  • Ingår i: New Waves in Epistemology. - 9780230537880 ; , s. 192-214
  • Bokkapitel (övrigt vetenskapligt/konstnärligt)
  •  
38.
  •  
39.
  • Olsson, Sven-Eric, et al. (författare)
  • Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection
  • 2009
  • Ingår i: Human Vaccines. - 1554-8600. ; 5:10, s. 696-704
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL (R)/SILGARD (R)) clinical program, 73% of women aged 16-26 were naive to all vaccine HPV types. In these women, prophylactic administration of the vaccine was highly effective in preventing HPV 6/11/16/18-related cervical disease. Of the remaining women, 15% of had evidence of past infection with one or more vaccine HPV types (seropositive and DNA negative) at the time of enrollment. Here we present an analysis in this group of women to determine the efficacy of the HPV 6/11/16/18 vaccine against new cervical and external anogenital disease related to the same vaccine HPV type which had previously been cleared. Vaccine tolerability in this previously infected population was also assessed. Results: Subjects were followed for an average of 40 months. Seven subjects in the placebo group developed cervical disease, and eight subjects developed external genital disease related to a vaccine HPV type they had previously encountered. No subject receiving HPV 6/11/16/18 vaccine developed disease to a vaccine HPV type to which they were seropositive and DNA negative at enrollment. Methods: 18,174 women were enrolled into three clinical studies. The data presented comprise a subset of these subjects (n = 2,617) who were HPV seropositive and DNA negative at enrollment (for >= 1 vaccine type). In each study, subjects were randomized in a 1:1 ratio to receive HPV 6/11/16/18 vaccine or placebo at day 1, month 2 and month 6 (without knowledge of baseline HPV status). Procedures performed for efficacy data evaluation included detailed genital examination, Pap testing and collection of cervicovaginal and external genital specimens. Analyses of efficacy were carried out in a population stratified by HPV serology and HPV DNA status at enrollment. Conclusions: These results suggest that natural HPV infection-elicited antibodies may not provide complete protection over time, however the immune response to the HPV 6/11/16/18 vaccine appears to prevent reinfection or reactivation of disease with vaccine HPV types. Vaccine-related adverse experiences were higher among subjects receiving vaccine, mostly due to increased injection site adverse experiences.
  •  
40.
  •  
41.
  • Persson, Johannes, et al. (författare)
  • Levi on the Reality of Dispositions
  • 2006
  • Ingår i: Knowledge and Inquiry. Essays on the Pragmatism of Isaac Levi. ; , s. 313-326
  • Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
    • Isaac Levi is more interested in inquiry and how it progresses than he is in metaphysics. Questions concerning the role of disposition predicates in inquiry are more central to him than those concerning the nature and reality of dispositions. It has not stopped him from giving me and others very useful metaphysical advice. Currently, where empirical metaphysics is in vogue, there is every reason to see whether the two forms of philosophical interest might interlock substantially. Levi has stimulating ideas indeed on the two forms of philosophical interest, and has recently summarized them in the slogan: “The reality of dispositions is a work in progress” (Levi 2003, p. 152). We can learn much about what kinds of dispositions are acceptable from tracing and comparing the histories of successful and less successful disposition predicates in scientific inquiry. Levi explores one route along which dispositions become real. His idea is that the introduction of dispositions facilitates covering law explanation by increasing the number of laws. The successful disposition predicate eventually becomes integrated in scientific theory, much like an ordinary theoretical term, whereas the unsuccessful does not. My impression is that Levi thinks that this is the only way a disposition can become real. To evaluate this claim, an alternative course suggested by Jon Elster is introduced. I then try to bring out the differences between Levi's and Elster's views on dispositions, partly by suggesting that they resemble two aspects of full explanations discussed by Wesley Salmon. But more about that below.
  •  
42.
  • Qiu, Zhijun, et al. (författare)
  • Role of Si implantation in control of underlap length in Schottky-barrier source/drain MOSFETs on ultrathin body SOI
  • 2008
  • Ingår i: Proceedings of ULIS. - NEW YORK : IEEE. ; , s. 175-178, s. 175-178
  • Konferensbidrag (refereegranskat)abstract
    • This works demonstrates a novel approach using Si implantation prior to Pt deposition and PtSi formation to control the underlap length between the PtSi source/drain regions to the gate in Schottky-Barrier (SB-) MOSFETs. Dopant segregation at the PtSi/Si interface is used to enhance device performance. With the lon /Ioff current ratio as an indicator, optimized Si implant doses are found for both n- and p-channel SB-MOSFETs. Through an effective barrier width, the underlap length has direct implication on the leakage current.
  •  
43.
  • Sahlin, Nils-Eric, et al. (författare)
  • Levi on risk
  • 2006
  • Ingår i: Knowledge and Inquiry: Essays on the Pragmatism of Isaac Levi. - 9780521845564
  • Bokkapitel (övrigt vetenskapligt/konstnärligt)
  •  
44.
  • Sanchez, W, et al. (författare)
  • A new ELISA for the three-spined stickleback (Gasterosteus aculeatus L.) spiggin, using antibodies against synthetic peptide
  • 2008
  • Ingår i: Comparative Biochemistry and Physiology - Part C. - New York, NY : Elsevier. - 1532-0456 .- 1878-1659. ; 147:1, s. 129-137
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of this study was to develop an enzyme-linked immunosorbent (ELISA) assay to quantify spiggin in the three-spined stickleback. Spiggin is a glue protein produced in the kidney of male three-spined stickleback under the control of androgens during the breeding period. Disturbances of spiggin production in male fish and abnormal induction of spiggin in female fish are considered as valuable biomarkers of exposure to (anti-)androgenic chemicals. Polyclonal antibodies against a peptide sequence of spiggin (HRD-16) were used and the specificity of the antibodies was verified by Western blotting and direct ELISA experiments. By using HRD-16 antibodies and spiggin standard preparation, a competitive ELISA was set-up and validated. This assay appears sensitive, with a detection limit of 0.5 U/mL, and specific, as shown by the competition curves, obtained by serial dilution of male and female kidney homogenates, that were parallel to the spiggin standard curves. The ability of the spiggin ELISA to quantify spiggin induction was achieved by exposing male and female three-spined sticklebacks to 0.1 and 1 microg/L of methyltestosterone. The results show a significant dose-dependent induction of spiggin in methyltestosterone-exposed female fish compared to controls.
  •  
45.
  •  
46.
  •  
47.
  • von Hofsten, Jonas, et al. (författare)
  • Determination of the expression pattern of the dual promoter of zebrafish fushi tarazu factor-1a following microinjections into zebrafish one cell stage embryos
  • 2005
  • Ingår i: General and Comparative Endocrinology. - San Diego : Academic Press. - 0016-6480 .- 1095-6840. ; 142:1-2, s. 222-226
  • Tidskriftsartikel (refereegranskat)abstract
    • The zebrafish fushi tarazu factor-1a (ff1a) is a transcription factor belonging to the NR5A subgroup of nuclear receptors. The NR5A receptors bind DNA as monomers and are considered to be orphans due to their ability to promote transcription of downstream genes without ligands. In zebrafish, four M homologues (Ff1a, Ff1b, Ff1c, and Ff1d) have been identified so far. The gene coding for Ff1a is driven by two separate promoters, and give rise to four splice variants. Ff1a is expressed in the somites and pronephric ducts during somitogenesis and in the brain, liver, and mandibular arch during later embryonic stages. In adults the gene is highly expressed in gonads, liver, and intestine, but can be detected in most tissues. The broad variety of embryonic expression domains indicates several important developmental features. One of the mammalian fushi tarazu factor-1 genes, steroidogenic factor-1 (SF-1), is essential for the development of gonads and adrenals. SF-1 is together with Sox9, WT1, and GATA4 a positive transcriptional regulator of human anti-mullerian hormone (AMH) and thereby linked to the male sex-determining pathway. The zebrafish ff1a dual promoter contains several GATA binding sites and E-boxes, a site for DR4, XFD2, MyoD, Snail, HNF3, S8, and an HMG-box recognition site for Sox9. In a first attempt to dissect the ff1a promoter in vivo we have produced first generation transgenes in order to determine the correlation between the expression of the endogenous ff1a gene and the microinjected ff1a a promoter coupled to the pEGFP reporter vector. Our results show that the microinjected constructs are expressed in the correct tissues.
  •  
48.
  • Zhang, Zhen, et al. (författare)
  • SB-MOSFETs in UTB-SOI featuring PtSi source/drain with dopant segregation
  • 2008
  • Ingår i: IEEE Electron Device Letters. - 0741-3106 .- 1558-0563. ; 29:1, s. 125-127
  • Tidskriftsartikel (refereegranskat)abstract
    • MOSFETs of both polarities with PtSi-based Schottky-barrier source/drain (S/D) have been fabricated in ultrathin-body Si-on-insulator. The PtSi is formed in the S/D regions without lateral silicide growth under the gate spacers. This design leads to a 30-nm underlap between the PtSi-Si contacts and the gate edges resulting in low drive currents. Despite the underlap, excellent performance is achieved for both types of MOSFETs with large drive currents and low leakage by means of dopant segregation through As and B implantation into the PtSi followed by drive-in annealing at low temperatures.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-48 av 48
Typ av publikation
tidskriftsartikel (21)
bokkapitel (9)
recension (7)
konferensbidrag (4)
samlingsverk (redaktörskap) (3)
bok (2)
visa fler...
forskningsöversikt (2)
visa färre...
Typ av innehåll
refereegranskat (28)
övrigt vetenskapligt/konstnärligt (20)
Författare/redaktör
Olsson, Erik J (34)
Olsson, Sven-Eric (5)
Dillner, Joakim (4)
Brown, Darron R. (4)
Kjaer, Susanne K. (4)
Hellström, Per-Erik (3)
visa fler...
Östling, Mikael (3)
Lehtinen, Matti (3)
Lu, J. (2)
Olsson, Jörgen, 1966 ... (2)
Olsson, Per-Erik (2)
Malm, Gunnar (2)
Eriksson, Anders (1)
Hansson, Bengt (1)
Liu, R. (1)
Blomberg, Lars G (1)
Kockum, I. (1)
Årzén, Karl-Erik (1)
Olsson, J. (1)
Persson, Johannes (1)
Larsson, A (1)
Karlsson, J. (1)
Olsson, E (1)
Sahlin, Nils-Eric (1)
Rollman, Ola (1)
André, Mats (1)
Andersson-Ellström, ... (1)
Pedersen, A. (1)
Lindqvist, Per-Arne (1)
Brion, F. (1)
Lie, Benedicte (1)
Wahlund, Jan-Erik (1)
Cambon-Thomsen, A (1)
von Hofsten, Jonas (1)
Zhang, Zhen (1)
Modig, Carina, 1963- (1)
Nerup, J (1)
Pociot, F (1)
Malm, Christian (1)
Olsson, Marita, 1965 (1)
Åhlen, Lennart (1)
Schroeder-Heister, P ... (1)
Holtet, J. A. (1)
Pritchard, Duncan (1)
Blomhoff, A (1)
Akselsen, HE (1)
Undlien, DE (1)
Torebjörk, Erik (1)
Olsson, G (1)
Boström, Rolf (1)
visa färre...
Lärosäte
Lunds universitet (40)
Kungliga Tekniska Högskolan (4)
Uppsala universitet (4)
Karolinska Institutet (4)
Göteborgs universitet (2)
Örebro universitet (2)
visa fler...
Umeå universitet (1)
Chalmers tekniska högskola (1)
visa färre...
Språk
Engelska (45)
Svenska (3)
Forskningsämne (UKÄ/SCB)
Humaniora (34)
Medicin och hälsovetenskap (7)
Teknik (4)
Naturvetenskap (3)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy